Psoriatic arthritis has targeted new drugs can be treated!The first and only targeted therapy

2022-05-22 0 By

Psoriatic arthritis in China finally has the first and only targeted therapy.On April 6, 2022, The National Medical Products Administration approved Reifu (upatinib sustained release tablets) for use in adult patients with active psoriatic arthritis (PsA) who have poor efficacy or intolerance to one or more DMARDs. The approval also opens a new era of PsA targeted therapy in China.PsA is a heterogeneous, systemic and inflammatory disease that can affect multiple body parts including joints and skin, such as peripheral arthritis, attachment inflammation, skin lesions, digitalization (toe) inflammation, axial involvement, digitalization (toe) a, etc.Inflammation caused by the immune system can cause pain, swelling and stiffness in the joints, and even irreversible joint damage, resulting in joint deformation and disability, which can seriously affect the quality of life of patients.According to The Consensus on diagnosis and Treatment of arthropathic psoriasis in China, the treatment options of PsA in China include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, biological agents and glucocorticoids, but no targeted drugs have been approved to treat the disease before.Clinical lack of innovative therapies that can comprehensively alleviate disease activity, patients’ treatment needs are far from being met.The approval of upatinib sustained-release tablets has greatly filled the gap in targeted therapy in the field of this disease, giving patients a more powerful weapon against the disease.Upatinib sustained Release tablet is an oral selective Janus kinase (JAK) inhibitor. The recommended dose is 15 mg once daily.The approval was based on data from the Phase 3 selECT-PSA 1 study, which compared the efficacy, safety and tolerability of remifu (upatinib sustained-release tablets) head-to-head with the biologic adamuzumab in patients with PsA.In this study, patients with active PsA treated with 15 mg upatinib showed efficacy on multiple disease activity indicators, with effective improvement in joint, body function, fatigue, and skin lesions, and the safety characteristics were consistent with those observed in patients with rheumatoid arthritis.”Many PsA patients have limited treatment options in China,” said Liu Yi, a Chinese principal investigator of the SELect-PSA 1 global study and a professor of rheumatology and Immunology at West China Hospital of Sichuan University.They are eager to find solutions that can help reduce joint pain, swelling and tenderness.With approval from the State Medical Products Administration, upatinib sustained Release tablet, the first targeted therapy for PsA in China, has the opportunity to help more patients suffering from signs and symptoms of psoriatic arthritis achieve meaningful remission and help them set and achieve treatment goals.”Upatinib sustained-release tablets have now received approval for a third indication in China, abbVie’s global vice president and General manager for China, John Osram, said.Notably, the study showed that the drug improved skin symptoms in PsA patients, with a PASI75 response rate of 63% at 16 weeks, compared with 21% of those who received placebo.However, the drug has not been studied in plaque psoriasis and is not intended to treat plaque psoriasis.Writing: Nandu reporter Zeng Wenqiong Intern: Guo Xinyang